Smaller companies can win acquisitions even when outbid by larger competitors by championing a collaborative integration. This involves a willingness to learn from and adopt the target company's superior processes, rather than simply imposing the acquirer's own systems, which appeals to founders who value their legacy.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

The success of an AI roll-up hinges on effective technology implementation. Therefore, the primary filter for acquiring a company is not just its financials but whether its leadership and culture are genuinely eager to adopt AI and transform their operations. This cultural fit is non-negotiable.

Successful large-scale acquirers remain nimble, flexing their own processes to suit the acquired company rather than force-fitting it into a rigid corporate structure. This preserves the culture and talent that made the company valuable, preventing value destruction and keeping the new team engaged.

When integrating acquired biotechs, Merck prioritizes retaining key talent and preserving ongoing science. The strategy involves immediate face-to-face engagement to reduce anxiety, followed by a pragmatic assessment of which processes must be standardized versus which can remain to avoid disrupting critical trials, a practice they call avoiding 'mercification'.

Instead of trying to merge broad cultural concepts, identify the target's key practices—like specific events or community work—and consciously continue them post-close. This maintains continuity and respects the acquired team’s identity far more than a values presentation.

Unlike typical pharma M&A where acquired executives depart, Eli Lilly retains and promotes talent from companies it buys, such as Jake Van Narden from Loxo Oncology. This tech-industry style "acqui-hire" strategy helps Lilly absorb entrepreneurial talent and institutional knowledge, embedding innovation directly into its senior leadership ranks.

For iCapital, an acquisition is not complete until both the technology and the people are fully integrated into a "one-eye capital" culture. The CEO emphasizes that people integration is even more critical than tech integration, as a failure on the cultural front means the entire acquisition fails.

Viewing acquisitions as "consolidations" rather than "roll-ups" shifts focus from simply aggregating EBITDA to strategically integrating culture and operations. This builds a cohesive company that drives incremental organic growth—the true source of value—rather than just relying on multiple arbitrage from increased scale.